Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Petition To Request an Exemption From 100 Percent Identity Testing of Dietary Ingredients: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 70876-70878 [2014-28087]
Download as PDF
70876
Federal Register / Vol. 79, No. 229 / Friday, November 28, 2014 / Notices
from 3,000 adult members in online
consumer panels maintained by a
contractor. The study plans to randomly
select 800 panel members in each of
three groups: Spanish-dominant
Hispanics, English-dominant Hispanics,
and English-speaking non-Hispanics.
Both English and Spanish
questionnaires will be used, as
appropriate. The study plans to include
topics such as: (1) Food safety
knowledge and attitude and (2) food
handling and consumption practice. To
help us understand the data, the study
will also collect information on
respondents’ background, including, but
not limited to, health status and
demographic characteristics, such as
age, gender, education, and income, and
degree of acculturation among Hispanic
respondents using a measure developed
by Marin, et al. (Ref. 6).
The study is part of our continuing
effort to protect the public health. We
will not use the results of the study to
develop population estimates. We will
use the results of the study to develop
followup quantitative and qualitative
research to gauge the prevalence and
extent of differences in food safety
knowledge and behaviors between the
three mentioned population groups. We
will use the results of the followup
research to help inform the design of
effective education and outreach
initiatives aimed at helping reduce the
risk of foodborne illness for the general
U.S. population as well as Hispanics.
We estimate the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
responses per
respondent
Number of
respondents
Activity
Total annual
responses
Average burden per response
Total hours
Cognitive interview screener .............
Cognitive interview ............................
Pretest invitation ...............................
Pretest ...............................................
Study invitation ..................................
Study .................................................
72
9
1,440
180
24,000
3,000
1
1
1
1
1
1
72
9
1,440
180
24,000
3,000
0.083 (5 minutes) .............................
0.5 (30 minutes) ...............................
0.033 (2 minutes) .............................
0.25 (15 minutes) .............................
0.033 (2 minutes) .............................
0.25 (15 minutes) .............................
6
5
48
45
792
750
Total ...........................................
........................
........................
........................
...........................................................
1,646
tkelley on DSK3SPTVN1PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
We base our estimates on prior
experience with research that is similar
to this proposed study. We will use a
cognitive interview screener with 72
individuals to recruit prospective
interview participants. We estimate that
it will take a screener respondent
approximately 5 minutes (0.083 hours)
to complete the cognitive interview
screener, for a total of 5.976 hours,
rounded to 6 hours. We will conduct
cognitive interviews with nine
participants. We estimate that it will
take a participant approximately 30
minutes to complete the interview, for
a total of 4.5 hours, rounded to 5 hours.
We also plan to conduct a pretest to
identify and resolve potential survey
administration problems. We will send
a pretest invitation to 1,440 prospective
pretest participants and estimate that it
will take a respondent approximately 2
minutes (0.033 hours) to complete the
invitation, for a total of 47.52 hours,
rounded to 48 hours. We will
administer the pretest with 180
participants and estimate that it will
take a participant 15 minutes (0.25
hours) to complete the pretest, for a total
of 45 hours. We will send a study
invitation to 24,000 prospective
participants and estimate that it will
take a respondent approximately 2
minutes (0.033 hours) to complete the
invitation, for a total of 792 hours. We
will administer the study with 3,000
participants and estimate that it will
take a participant 15 minutes (0.25
VerDate Sep<11>2014
17:31 Nov 26, 2014
Jkt 235001
hours) to complete the study, for a total
of 750 hours. The total estimated burden
for all the study activities is 1,646
hours.
Dated: November 21, 2014.
Leslie Kux,
Associate Commissioner for Policy.
II. References
BILLING CODE 4164–01–P
1. FDA. ‘‘Foodborne Illness & Contaminants.’’
June 9, 2014. Available at https://
www.fda.gov/Food/
FoodborneIllnessContaminants/
default.htm.
2. Passel, J. S. and D’V. Cohn. ‘‘U.S.
Population Projections: 2005–2050.’’
Pew Research Center. Washington, DC
February 11, 2008. Available at https://
pewhispanic.org/files/reports/85.pdf.
3. Quinlan, J. J. ‘‘Foodborne Illness Incidence
Rates and Food Safety Risks for
Populations of Low Socioeconomic
Status and Minority Race/Ethnicity: A
Review of the Literature.’’ International
Journal of Environmental Research and
Public Health, 10(8): 3634–3652. 2013.
´
4. Taylor, P., M. H. Lopez, J. Martınez, and
G. Velasco. ‘‘Language Use Among
Latinos.’’ Pew Research Center.
Washington, DC April 4, 2012. Available
at https://www.pewhispanic.org/2012/04/
04/iv-language-use-among-latinos/.
5. Henley, S. C., S. E. Stein, and J. J. Quinlan.
‘‘Identification of Unique Food Handling
Practices That Could Represent Food
Safety Risks for Minority Consumers.’’
Journal of Food Protection, 75: 2050–
2054. 2012.
6. Marin, G., F. Sabogal, B. V. Marin, et al.
‘‘Development of a Short Acculturation
Scale for Hispanics.’’ Hispanic Journal of
Behavioral Sciences, 9(2): 183–205.
1987.
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
[FR Doc. 2014–28088 Filed 11–26–14; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1152]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Petition To
Request an Exemption From 100
Percent Identity Testing of Dietary
Ingredients: Current Good
Manufacturing Practice in
Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary
Supplements
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
SUMMARY:
E:\FR\FM\28NON1.SGM
28NON1
70877
Federal Register / Vol. 79, No. 229 / Friday, November 28, 2014 / Notices
Fax written comments on the
collection of information by December
29, 2014.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0608. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd.; COLE–14526, Silver
Spring, MD 20993–0002 PRAStaff@
fda.hhs.gov.
DATES:
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Petition to Request an Exemption
from 100 Percent Identity Testing of
Dietary Ingredients:
SUPPLEMENTARY INFORMATION:
Current Good Manufacturing Practice
in Manufacturing, Packaging, Labeling,
or Holding Operations for Dietary
Supplements—21 CFR 111.75(a)(1)(ii)
(OMB Control Number 0910–0608)—
Reinstatement
The Dietary Supplement Health and
Education Act (DSHEA) (Pub. L. 103–
417) added section 402(g) of the Federal
Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 342(g)), which provides,
in part, that the Secretary of Health and
Human Services (the Secretary) may, by
regulation, prescribe good
manufacturing practices for dietary
supplements. Section 402(g)(1) of the
FD&C Act states that a dietary
supplement is adulterated if ‘‘it has
been prepared, packed, or held under
conditions that do not meet current
good manufacturing practice
regulations.’’ Section 701(a) of the FD&C
Act (21 U.S.C. 371(a)) gives us the
authority to issue regulations for the
efficient enforcement of the FD&C Act.
Part 111 of our regulations (21 CFR
part 111) establishes the minimum
current good manufacturing practice
(CGMP) necessary for activities related
to manufacturing, packaging, labeling,
or holding dietary supplements to
ensure the quality of the dietary
supplement. Section 111.75(a)(1) of our
regulations establishes a procedure for a
petition to request an exemption from
100 percent identity testing of dietary
ingredients. In accordance with
§ 111.75(a)(1)(ii), manufacturers may
request an exemption from the
requirements set forth in
§ 111.75(a)(1)(i) when the dietary
ingredient is obtained from one or more
suppliers identified in the petition. The
regulation clarifies that we are willing to
consider, on a case-by-case basis, a
manufacturer’s conclusion, supported
by appropriate data and information in
the petition submission, that it has
developed a system that it would
implement as a sound, consistent means
of establishing, with no material
diminution of assurance compared to
the assurance provided by 100 percent
identity testing, the identity of the
dietary ingredient before use.
Section 111.75(a)(1) reflects our
determination that manufacturers that
test or examine 100 percent of the
incoming dietary ingredients for
identity can be assured of the identity
of the ingredient. However, we
recognize that it may be possible for a
manufacturer to demonstrate, through
various methods and processes in use
over time for its particular operation,
that a system of less than 100 percent
identity testing would result in no
material diminution of assurance of the
identity of the dietary ingredient as
compared to the assurance provided by
100 percent identity testing. To provide
an opportunity for a manufacturer to
make such a showing and reduce the
frequency of identity testing of
components that are dietary ingredients
from 100 percent to some lower
frequency, we added to § 111.75(a)(1),
an exemption from the requirement of
100 percent identity testing when a
manufacturer petitions the Agency for
such an exemption to 100 percent
identity testing under § 10.30 and the
Agency grants such exemption. Such a
procedure would be consistent with our
stated goal, as described in the CGMP
final rule, of providing flexibility in the
CGMP requirements. Section
111.75(a)(1)(ii) sets forth the
information a manufacturer is required
to submit in such a petition. The
regulation also contains a requirement
to ensure that the manufacturer keeps
our response to a petition submitted
under § 111.75(a)(1)(ii) as a record
under § 111.95. The collection of
information in § 111.95 has been
approved under OMB control number
0910–0606.
Description of Respondents: The
respondents to this collection of
information are firms in the dietary
supplement industry, including dietary
supplement manufacturers, packagers
and re-packagers, holders, labelers and
re-labelers, distributors, warehouses,
exporters, importers, large businesses,
and small businesses.
In the Federal Register of November
14, 2013 (78 FR 68453), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. While three comments
were received, none were responsive to
the four collection of information topics
solicited in the notice and therefore are
not discussed in this document.
Additionally, although FDA was unable
to publish a 30 day notice before the
information collection expiration and is
therefore requesting its reinstatement,
the Agency has not conducted or
sponsored any collection of information
under OMB control number 0910–0608
in the interim period.
We estimate the annual burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR Section; CGMP requirements for dietary
supplements
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
111.75(a)(1)(ii) .....................................................................
1
1
1
8
8
tkelley on DSK3SPTVN1PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
In the last 3 years, we have not
received any new petitions to request an
exemption from 100 percent identity
testing of dietary ingredients; therefore,
the Agency estimates that one or fewer
VerDate Sep<11>2014
16:58 Nov 26, 2014
Jkt 235001
petitions will be submitted annually.
Based on our experience with petition
processes, we estimate it will take a
requestor about 8 hours to prepare the
factual and legal information necessary
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
to support a petition for exemption and
to prepare the petition. Although we
have not received any new petitions to
request an exemption from 100 percent
identity testing of dietary ingredients in
E:\FR\FM\28NON1.SGM
28NON1
70878
Federal Register / Vol. 79, No. 229 / Friday, November 28, 2014 / Notices
the last 3 years, we believe that OMB
approval of these information collection
provisions should be extended to
provide for the potential future need of
a firm in the dietary supplement
industry to petition for an exemption
from 100 percent identity testing of
dietary ingredients.
Dated: November 21, 2014.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2014–28087 Filed 11–26–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–D–1981]
The Drug Supply Chain Security Act
Standards for the Interoperable
Exchange of Information for Tracing of
Certain Human, Finished, Prescription
Drugs: How To Exchange Product
Tracing Information; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘DSCSA Standards for
the Interoperable Exchange of
Information for Tracing of Certain
Human, Finished, Prescription Drugs:
How To Exchange Product Tracing
Information.’’ The draft guidance
addresses the drug supply chain
security provisions of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act),
which requires the Secretary of the
Department of Health and Human
Services to establish initial standards for
the interoperable exchange of
transaction information, transaction
history, and transaction statements, in
paper or electronic format. Specifically,
the guidance establishes standards for
how transaction information,
transaction history, and transaction
statements should be exchanged among
trading partners through the extension
and/or use of current systems and
processes.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by January 27,
2015. Submit either electronic or
written comments concerning the
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:58 Nov 26, 2014
Jkt 235001
collection of information proposed in
the draft guidance by January 27, 2015.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993; or
the Office of Communication, Outreach
and Development, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Office of Compliance, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–3100,
drugtrackandtrace@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
On November 27, 2013, the Drug
Supply Chain Security Act (Title II of
Public Law 113–54) was signed into
law. Section 202 of the Drug Supply
Chain Security Act (DSCSA), which
adds new sections 581 and 582 to the
FD&C Act (21 U.S.C. 360eee and
360eee–1), sets forth new definitions
and requirements related to product
tracing. The DSCSA outlines critical
steps to build an electronic,
interoperable system by November 27,
2023, that will identify and trace certain
prescription drugs as they are
distributed within the United States.
Starting in 2015, certain trading
partners (manufacturers, wholesale
distributors, dispensers, and
repackagers) are required under sections
582(b)(1), (c)(1), (d)(1), and (e)(1) of the
FD&C Act to capture, maintain, and
provide the subsequent purchaser with
transaction information, transaction
history, and a transaction statement
(product tracing information) for certain
prescription drug products.
Manufacturers, wholesale distributors,
and repackagers must meet these
requirements by January 1, 2015;
dispensers must meet them by July 1,
2015. In addition, each manufacturer,
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
wholesale distributor, dispenser, and
repackager must comply with all
applicable requirements in the event
they meet the definition of more than
one trading partner under section
582(a)(1), but trading partners are not
required to duplicate requirements.
Section 582(a)(2)(A) of the FD&C Act
directs FDA to establish initial
standards to facilitate the interoperable
exchange of transaction information,
transaction history, and transaction
statements between trading partners.
FDA obtained stakeholder input on
the development of the initial standards
for the interoperable exchange of
product tracing information, in paper
and electronic formats, through a public
docket established in February 2014, as
required under section 582(a)(2)(B), and
a public workshop that was held May 8
and 9, 2014. The public workshop
provided a forum for FDA to obtain
input from stakeholders in the
pharmaceutical distribution supply
chain on how trading partners can best
comply with the requirements for the
interoperable exchange of product
tracing information beginning in 2015,
using currently available standards or
practices. Comments to the public
dockets and from the workshop were
considered in the development of this
guidance, and will be considered in
developing additional guidance to
further elaborate on the standards for
the interoperable exchange of product
tracing information.
This initial draft guidance establishes
standards to help trading partners
comply with the requirements of
sections 582(b)(1), (c)(1), (d)(1), and
(e)(1) of the FD&C Act to provide the
subsequent trading partners with
product tracing information, in paper or
electronic format, through the extension
and/or use of current systems and
processes. Under these provisions,
trading partners are also required to
capture and maintain the applicable
product tracing information for not less
than 6 years after the date of the
transaction. Implementation of these
provisions will help further improve the
security of the pharmaceutical
distribution supply chain and increase
confidence in the safety and
authenticity of human prescription
drugs. FDA intends to issue additional
guidance to facilitate the interoperable
exchange of product tracing information
through standardization of data and
documentation practices.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
This guidance is marked as a ‘‘draft’’
consistent with its description in
section 582(a)(2)(A) of the FD&C Act.
E:\FR\FM\28NON1.SGM
28NON1
Agencies
[Federal Register Volume 79, Number 229 (Friday, November 28, 2014)]
[Notices]
[Pages 70876-70878]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-28087]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1152]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Petition To Request
an Exemption From 100 Percent Identity Testing of Dietary Ingredients:
Current Good Manufacturing Practice in Manufacturing, Packaging,
Labeling, or Holding Operations for Dietary Supplements
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
[[Page 70877]]
DATES: Fax written comments on the collection of information by
December 29, 2014.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0608.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd.; COLE-14526, Silver
Spring, MD 20993-0002 PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Petition to Request an Exemption from 100 Percent Identity Testing
of Dietary Ingredients:
Current Good Manufacturing Practice in Manufacturing, Packaging,
Labeling, or Holding Operations for Dietary Supplements--21 CFR
111.75(a)(1)(ii) (OMB Control Number 0910-0608)--Reinstatement
The Dietary Supplement Health and Education Act (DSHEA) (Pub. L.
103-417) added section 402(g) of the Federal Food, Drug, and Cosmetic
Act (FD&C Act) (21 U.S.C. 342(g)), which provides, in part, that the
Secretary of Health and Human Services (the Secretary) may, by
regulation, prescribe good manufacturing practices for dietary
supplements. Section 402(g)(1) of the FD&C Act states that a dietary
supplement is adulterated if ``it has been prepared, packed, or held
under conditions that do not meet current good manufacturing practice
regulations.'' Section 701(a) of the FD&C Act (21 U.S.C. 371(a)) gives
us the authority to issue regulations for the efficient enforcement of
the FD&C Act.
Part 111 of our regulations (21 CFR part 111) establishes the
minimum current good manufacturing practice (CGMP) necessary for
activities related to manufacturing, packaging, labeling, or holding
dietary supplements to ensure the quality of the dietary supplement.
Section 111.75(a)(1) of our regulations establishes a procedure for a
petition to request an exemption from 100 percent identity testing of
dietary ingredients. In accordance with Sec. 111.75(a)(1)(ii),
manufacturers may request an exemption from the requirements set forth
in Sec. 111.75(a)(1)(i) when the dietary ingredient is obtained from
one or more suppliers identified in the petition. The regulation
clarifies that we are willing to consider, on a case-by-case basis, a
manufacturer's conclusion, supported by appropriate data and
information in the petition submission, that it has developed a system
that it would implement as a sound, consistent means of establishing,
with no material diminution of assurance compared to the assurance
provided by 100 percent identity testing, the identity of the dietary
ingredient before use.
Section 111.75(a)(1) reflects our determination that manufacturers
that test or examine 100 percent of the incoming dietary ingredients
for identity can be assured of the identity of the ingredient. However,
we recognize that it may be possible for a manufacturer to demonstrate,
through various methods and processes in use over time for its
particular operation, that a system of less than 100 percent identity
testing would result in no material diminution of assurance of the
identity of the dietary ingredient as compared to the assurance
provided by 100 percent identity testing. To provide an opportunity for
a manufacturer to make such a showing and reduce the frequency of
identity testing of components that are dietary ingredients from 100
percent to some lower frequency, we added to Sec. 111.75(a)(1), an
exemption from the requirement of 100 percent identity testing when a
manufacturer petitions the Agency for such an exemption to 100 percent
identity testing under Sec. 10.30 and the Agency grants such
exemption. Such a procedure would be consistent with our stated goal,
as described in the CGMP final rule, of providing flexibility in the
CGMP requirements. Section 111.75(a)(1)(ii) sets forth the information
a manufacturer is required to submit in such a petition. The regulation
also contains a requirement to ensure that the manufacturer keeps our
response to a petition submitted under Sec. 111.75(a)(1)(ii) as a
record under Sec. 111.95. The collection of information in Sec.
111.95 has been approved under OMB control number 0910-0606.
Description of Respondents: The respondents to this collection of
information are firms in the dietary supplement industry, including
dietary supplement manufacturers, packagers and re-packagers, holders,
labelers and re-labelers, distributors, warehouses, exporters,
importers, large businesses, and small businesses.
In the Federal Register of November 14, 2013 (78 FR 68453), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. While three comments were received, none
were responsive to the four collection of information topics solicited
in the notice and therefore are not discussed in this document.
Additionally, although FDA was unable to publish a 30 day notice before
the information collection expiration and is therefore requesting its
reinstatement, the Agency has not conducted or sponsored any collection
of information under OMB control number 0910-0608 in the interim
period.
We estimate the annual burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section; CGMP requirements for dietary supplements Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.75(a)(1)(ii)................................................... 1 1 1 8 8
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
In the last 3 years, we have not received any new petitions to
request an exemption from 100 percent identity testing of dietary
ingredients; therefore, the Agency estimates that one or fewer
petitions will be submitted annually. Based on our experience with
petition processes, we estimate it will take a requestor about 8 hours
to prepare the factual and legal information necessary to support a
petition for exemption and to prepare the petition. Although we have
not received any new petitions to request an exemption from 100 percent
identity testing of dietary ingredients in
[[Page 70878]]
the last 3 years, we believe that OMB approval of these information
collection provisions should be extended to provide for the potential
future need of a firm in the dietary supplement industry to petition
for an exemption from 100 percent identity testing of dietary
ingredients.
Dated: November 21, 2014.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2014-28087 Filed 11-26-14; 8:45 am]
BILLING CODE 4164-01-P